[A Markov model to access long-term effects of rosiglitazone natrium on the treatment of type 2 diabetes].
The aim of this study was to estimate the long-term treatment effects of Rosiglitazone-natrium in type 2 diabetes. A Markov decision model was developed to predict, over 10 years, mortality with or without Rosiglitazone-natrium treatment. During 10 years research, 14.2% patients developed to complications of type 2 diabetes mellitus, 3.8% patients should be dead in Rosiglitazone-natrium treatment group. 22.7% patients developed to complications of type 2 diabetes, 6.6% patients should be dead in non-Rosiglitazone-natrium treatment group. Markov decision model should be useful in accessing the long-term effects of drug treatment. Evidence on long-term benefit of Rosiglitazone-natrium could be of importance for future decision making.